Tetomilast. Otsuka Phamaceutical

IDrugs

Volumn 8, Issue 6, 2005, Pages 502-507

  O'Mahony, Seamus ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; SALAZOSULFAPYRIDINE; TETOMILAST; UNCLASSIFIED DRUG; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE MODEL; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DYSPEPSIA; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; RANDOMIZATION; REMISSION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SWEATING; ULCERATIVE COLITIS; VOMITING; ANIMAL; ARTICLE; DRUG EFFECT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SYNTHESIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COLITIS, ULCERATIVE; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 20344407786     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. 172187 Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: Synthesis and structure-activity relationships. Chihiro M, Nagamoto H, Takemura I, Kitano K, Komatsu H, Sekiguchi K, Tabusa F, Mori T, Tominaga M, Yabuuchi Y J MED CHEM 1995 38 2 353-358
2. 282784 The Japanese Pharmacological Society 71st Annual Meeting Kyoto International Conference Center, Kyoto, Japan. Wright T IDDB MEETING REPORT 1998 March 23-26
3. 289172 OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury. Bloomfield GL, Ridings PC, Blocher CR, Fisher BJ, Sugerman HJ, Nagamoto H, Fowler AA J SURG RES 1997 72 1 70-77
4. 289174 A novel compound OPC-6535 inhibits leukocyte activation and reduces infarct size after 5 hr reperfusion in a porcine myocardial infarction model. Onogawa T, Nagamoto H, Maeda T, Aoyama M, Miyakoda G, Sumida T, Mori T JAP J PHARMACOL 1998 79 Suppl 1 80P
5. 289175 OPC-6535, an inhibitor of leukocyte activation, improves the left ventricular dysfunction in porcine myocardial infarction model after long term reperfusion. Miyakoda G, Nagamoto H, Maeda T, Ohura M, Sumida T, Tominaga M, Mori T JPN J PHARMACOL 1998 79 Suppl 1 Abs 0-148
6. 404118 Protective effect of OPC-6535, a superoxide anion production inhibitor, on liver grafts subjected to warm ischemia during porcine liver transplantation. Ejiri S, Eguchi Y, Kishida A, Kurumi Y, Tani T, Kodama M TRANSPLANT PROC 2000 32 3 318-321
7. 404127 The effects of OPC-6535 in liver dysfunction induced with LPS administration. Nomura H, Haji S, Yasuda K, Ohyanagi H, Nagamoto H GASTROENTEROLOGY 1999 116 4 Pt 2 A1338
8. 417198 Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Souness JE, Aldous D, Sargent C IMMUNOPHARMACOLOGY 2000 47 2-3 127-162
9. 463513 A practical synthesis of 3,4-diethoxybenzthioamide based on Friedel Crafts reaction with potassium thiocyanate in methanesulfonic acid. Aki S, Fujioka T, Ishigami M, Minamikawa J BIOORG MED CHEM LETT 2002 12 17 2317-2320
10. 498405 Otsuka initiates phase III clinical trials on compound for ulcerative colitis. Otsuka Pharmaceutical Co Ltd PRESS RELEASE 2003 July 22
11. 537688 OPC-6535, a novel oral thiazole compound, suppresses colonic damage in a rat model of TNBS-induced colitis. Nagamoto H, Maeda T, Haruta JP, Miyakoda G, Sekiguchi K, Osaka T, Nakashima T, Kikuchi M GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs M1044
12. 537689 OPC-6535 suppresses symptoms and colonic damage in a rat model of DSS-induced chronic colitis. Nagamoto H, Maeda T, Haruta JP, Miyakoda G, Mori T, Tominaga M GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs M1045
13. 538383 Randomized, double-blind, placebo-controlled, parallel arm, safety and efficacy trial of once-daily, oral OPC-6535 in the treatment of active ulcerative colitis (UC). Hanauer SB, Miner PB, Keshavarzian A, Isaacs, KL, Goff JS, Harris MS GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs 814
14. 538557 OPC-6535 inhibits human and porcine monocyte tumor necrosis factor-α production in vitro and in vivo. Nagamoto H, Maeda T, Sueyoshi S, Aoyama M, Onogawa T, Miyakoda G, Mori T GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs W1090
15. 539076 Digestive Disease Week 2004 (Part II). Gotham S IDDB MEETING REPORT 2004 May 15-20
16. 539241 Data presented at digestive disease week on two Otsuka products in development for inflammatory bowel disease. Otsuka America Pharmaceutical Inc PRESS RELEASE 2004 May 18
17. 540043 Digestive Disease Week (Part IV). Gotham S IDDB MEETING REPORT 2004 May 15-20
18. 548329 Therapy for chronic obstructive pulmonary disease in the 21st century. Donnelly LE, Rogers DF DRUGS 2003 63 19 1973-1998
19. 549373 Effects of intravenous or oral administration of OPC-6535 in a rat model of 2,4,6,-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Maeda T, Sueyoshi S, Aoyama M, Nagamoto H, Miyakode G MT, Tominaga M GUT 1997 41 Suppl 3 A112
20. 571881 Otsuka Maryland Research Institute Inc - Pipeline. Otsuka Pharmaceutical Co Ltd COMPANY WORLD WIDE WEB SITE 2004 November 18
21. 580662 PDE4 Inhibition: A novel approach for the treatment of inflammatory bowel disease. Banner KH, Trevethick MA TRENDS PHARMACOL SCI 2004 25 8 430-436
22. 583773 Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth BJ LANCET 2005 365 9454 167-175
23. 591089 Synthesis and biological evaluation of neutrophilic inflammation inhibitors. Bruno O, Brullo C, Arduino N, Schenone S, Ranise A, Bondavalli F, Ottonello L, Dapino P, Dallegri F FARMACO 2004 59 3 223-235
24. 594469 Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. THORAX 2004 59 1:1 232
25. 594471 Corticosteroids: Clinical pharmacology and therapeutic use. Swartz SL, Dluhy RG DRUGS 1978 16 3 238-255
26. 594472 A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Cohen RD, Woseth DM, Thisted RA, Hanauer SB AM JOURNAL GASTROENTEROL 2000 95 5 1263-1276
27. 594474 Ciclosporin and refractory colitis. Hawthorne AB EUR J GASTROENTEROL HEPATOL 2003 15 3 239-244
28. 594481 Predicting outcome in severe ulcerative colitis. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP GUT 1996 38 6 905-910
29. 594485 Cilomilast (Ariflo) a potent selective phosophodiesterase 4 inhibitor reduces exacerbations in COPD patients: Results of a six month trial. Eddleston JD, Compton CH, Nieman R et al AM J RESPIR CRIT CARE MED 2001 163 A277
30. 594486 Roflumilast, a novel selective phosphodiesterase 4 inhibitor improves lung function in patients with moderate to severe COPD. Rabe KF, Chapman KR, Jubert J, Witte S, Bredenbroeker D AM J RESPIR CRIT CARE MED 2004 169 A518
31. 597667 Phosphodiesterase isoenzymes: Molecular targets for novel antiasthma agents. Torphy TJ AM J RESPIR CRIT CARE MED 1998 157 2 351-370